{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:28:15Z","timestamp":1787538495214,"version":"build-2736575974"},"reference-count":58,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,7,23]],"date-time":"2007-07-23T00:00:00Z","timestamp":1185148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cellular Biochemistry"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Melanoma is a disease which has been shown to be responsive to immune intervention. This has been suggested by reports of spontaneous responses of metastatic disease with strong immune infiltrates, and supported by recent data correlating clinical response after IFN\u03b1 treatment with development of generalized autoimmunity. Since the identification of melanoma\u2010associated tumor antigens, many groups have performed clinical trials to take advantage of this discovery with melanoma\u2010specific cancer vaccines. These trials, in which multiple antigen delivery strategies have been tested in hundreds of patients, have demonstrated that these vaccines are safe, immunogenic, and yield a low frequency of objective clinical responses. The ability to perform careful immunological monitoring has allowed important insights into the nature of the anti\u2010tumor immunity generated by these vaccinations. While many trials have found that the absolute frequency of T cells specific for a vaccine\u2010encoded antigen are a marker of immunization, it does not correlate with objective clinical response. Induction of broad immunity to multiple tumor antigens, taking advantage of cross\u2010reactive T cells and activation of persistent T cells may be more important. Harnessing additional modes of amplifying immune responses (lymphodepletion, cytokine support, inhibition of negative immune self\u2010regulation) are now being tested and should improve clinical responses from 5% to 10% complete response seen currently. J. Cell. Biochem. 102: 301\u2013310, 2007. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcb.21473","type":"journal-article","created":{"date-parts":[[2007,7,23]],"date-time":"2007-07-23T16:16:27Z","timestamp":1185207387000},"page":"301-310","source":"Crossref","is-referenced-by-count":36,"title":["Melanoma cancer vaccines and anti\u2010tumor T cell responses"],"prefix":"10.1002","volume":"102","author":[{"given":"Lazar","family":"Vujanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,23]]},"reference":[{"key":"e_1_2_4_2_1","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor\u2010derived dendritic cell vaccine","volume":"61","author":"Banchereau J","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_4_3_1","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.4049\/jimmunol.158.10.4543","article-title":"In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model","volume":"158","author":"Barratt\u2010Boyes SM","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2487"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.725"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1997.0105"},{"key":"e_1_2_4_7_1","first-page":"3134","article-title":"Generation of human T\u2010cell responses to an HLA\u2010A2.1\u2010restricted peptide epitope derived from alpha\u2010fetoprotein","volume":"59","author":"Butterfield LH","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_4_8_1","first-page":"998","article-title":"Determinant spreading associated with clinical response in dendritic cell\u2010based immunotherapy for malignant melanoma","volume":"9","author":"Butterfield LH","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.13.7663-7668.2003"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2039"},{"key":"e_1_2_4_11_1","first-page":"1021","article-title":"A phase I trial of tumor lysate\u2010pulsed dendritic cells in the treatment of advanced cancer","volume":"8","author":"Chang AE","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200409000-00005"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5"},{"key":"e_1_2_4_14_1","first-page":"37","article-title":"Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART\u20101\/Melan A [see comments]","volume":"3","author":"Cormier JN","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1997.16"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00012"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197811)42:5<2282::AID-CNCR2820420528>3.0.CO;2-V"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2421"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1450"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(97)01217-6"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0429-0"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.3.1338"},{"key":"e_1_2_4_23_1","first-page":"2479","article-title":"Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE\u20101 peptide loaded antigen presenting cell\u2010based vaccine","volume":"56","author":"Hu X","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008864200"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006220707618"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000162780.96310.e4"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2061"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.647"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.6.1005"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.1100"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(98)01299-7"},{"key":"e_1_2_4_32_1","first-page":"8782","article-title":"alpha\u2010Fetoprotein\u2010specific tumor immunity induced by plasmid prime\u2010adenovirus boost genetic vaccination","volume":"61","author":"Meng WS","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082120099"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.17.8078"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200007000-00003"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1163"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211309.90621.8b"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199601270-00019"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.144"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.9.6527"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-005-1825-9"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200409000-00004"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-321"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.24.1894"},{"key":"e_1_2_4_46_1","first-page":"2973","article-title":"Recombinant fowlpox viruses encoding the anchor\u2010modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma","volume":"9","author":"Rosenberg SA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_47_1","first-page":"967","article-title":"T\u2010cell responses against tyrosinase 368\u2013376(370D) peptide in HLA*A0201+ melanoma patients: Randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony\u2010stimulating factor, and QS\u201021 as immunological adjuvants","volume":"8","author":"Schaed SG","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20012100"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.11.040193.003501"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/415331a"},{"key":"e_1_2_4_51_1","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100(280\u2013288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes","volume":"7","author":"Slingluff CL","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.212"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21669"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23373"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2325::AID-CNCR22>3.0.CO;2-Y"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.69.6.937"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(97)80050-7"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1840703"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001099900042"}],"container-title":["Journal of Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcb.21473","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcb.21473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:09:18Z","timestamp":1700064558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcb.21473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,23]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/jcb.21473"],"URL":"https:\/\/doi.org\/10.1002\/jcb.21473","archive":["Portico"],"relation":{},"ISSN":["0730-2312","1097-4644"],"issn-type":[{"value":"0730-2312","type":"print"},{"value":"1097-4644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,23]]}}}